CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 119 enrolled
Drug / intervention
A single "booster" dose of the Moderna mRNA COVID-19 vaccinedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05028374
NCT05028374Phase 2Completed
CompareCT.gov

Phase II Trial Evaluating the Efficacy of Moderna COVID-19 Vaccine Booster Dosing in Patients With Hematologic Malignancies Who Did Not Have an Adequate Response to Prior Vaccination

Barbara Ann Karmanos Cancer Institute·interventional·Posted Aug 31, 2021·Updated Dec 20, 2023

In Brief

A Phase 2 clinical trial evaluating A single "booster" dose of the Moderna mRNA COVID-19 vaccine for Multiple Myeloma and 2 related conditions. Completed, enrolled 119 participants across 1 site.

Detailed Summary

To determine whether protective antibody levels increase after booster dosing with the Moderna COVID-19 vaccine in patients diagnosed with Hematologic Malignancies who have low antibody levels after a prior first vaccination with any of the SARS-CoV2 vaccines that were authorized for use in the USA. Researchers will also assess whether the booster dosing with the Moderna COVID-19 vaccine is safe in patients with multiple myeloma, amyloidosis, or other blood cancers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMultiple Myeloma, AL Amyloidosis, Chronic Lymphocytic Leukemia
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20222023202420252026
First PostedAug 31, 2021
Enrollment StartAug 17, 2021
Primary CompletionNov 2, 2021
TodayJul 2, 2026
Enrollment to primary: 3 monthsPosted 4.8 years ago

Interventions

A single "booster" dose of the Moderna mRNA COVID-19 vaccinedrug

All participants will receive a single dose of the Moderna mRNA COVID-19 vaccine administered intramuscularly. This is an open label, non-randomized trial.